Zhi Tong Cai Jing·2025-09-22 11:34Core Viewpoint - The company announced that its subsidiary, Guangzhou Baiyunshan Guanghua Pharmaceutical Co., Ltd., has registered the Phase II clinical trial for its pediatric Xiaochaihu granules, focusing on the treatment of pediatric gastrointestinal colds [1] Group 1: Clinical Trial Information - The Phase II clinical trial is designed as a randomized, double-blind, parallel-controlled, multi-center study to evaluate the efficacy and safety of pediatric Xiaochaihu granules for treating pediatric gastrointestinal colds [1] - The pediatric Xiaochaihu granules are primarily used for treating pediatric gastrointestinal colds, specifically targeting the "邪犯少阳证" syndrome [1] Group 2: Regulatory Approvals - Guanghua Pharmaceutical received the clinical trial approval notice from the National Medical Products Administration in May 2023 [1] - Following the approval, the company completed the ethical review and obtained the ethical approval to proceed with the Phase II clinical trial of pediatric Xiaochaihu granules [1]